Cardiovascular Conference Series: Anticoagulant Therapy – Beyond Clinical Trials
Patients who have had a venous thromboembolic event are generally advised to receive anticoagulant treatment for three months or longer to prevent a recurrent episode. Current guidelines recommend initial heparin and an oral vitamin K antagonist (VKA) for long-term anticoagulation. However, because of the well-described disadvantages of VKAs, including extensive food and drug interactions and the need for regular anticoagulation monitoring, novel oral anticoagulants (NOACs) have become an attractive option in recent years. Dr. Turpie will discuss results from the most recent NOACs trials, and their impact on the prevention and management of anticoagulation.
Cardiologists, Interventional Cardiologists, Interventional Radiologists, General Internists, Primary Care Physicians, Intensivists, Pulmonologists, General Surgeons, Orthopedic Surgeons, Urologists, Gynecologists, Anesthesiologists, Emergency Medicine Physicians, Hospitalists, Physicain Assistants, Nurse Practitioners, Nurses, Radiologic Technologists, Ultrasound Technologists, Laboratory Technicians, Pharmacists, Respiratory Technologists and other interested healthcare providers.
- Analyze clinical studies of non-vitamin K antagonist oral anticoagulants (NOACs) and their impact on prevention and treatment of venous thromboembolism (VTE).
- Differentiate Phase III clinical trials and Post-authorization Studies of NOACs.
- Implement strategies for the proper management and reversal of NOACs.
Pre-registration is required. Please log in to register.
|Live event - Baptist Hospital - 5MCVI|
|Videoconference to South Miami Hospital - MCVI 2nd fl. Conference Room|
|Videoconference to Homestead Hospital - Pineapple Room|
|Videoconference to West Kendall Baptist Hospital - ED Conference Room|
Alexander G. G. Turpie, M.D., FRCP, FACP, FACC, FRCPC
Professor of Medicine
Hamilton, Ontario, Canada
Dr. Alexander G.G. Turpie has indicated that he is a consultant for Bayer Pharmaceutical and Portola Pharmaceutical and is a member of the Speakers Bureau.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Florida Board of Laboratory Personnel
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
- 1.00 Florida Board of Occupational Therapy
- 1.00 Florida Board of Pharmacy
- 1.00 Florida Board of Psychology
- 1.00 Florida Board of Respiratory Therapy
Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.